Knee osteoarthritis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Aged 18 - 65 years old; 2) Gender: no limit; 3) History of primary osteoarthritis of the knee characterized by knee pain; or visual analog score of joint pain (VAS) = 2.5, or MRI diagnosed as osteoarthritis, or based on Kellgren-Lawrence grading criteria, knee joint X-ray diagnosis was grade II-IV osteoarthritis; 4) Area of cartilage defect: 2-6 cm2; serum collagen II is higher than normal; 5) Patients have difficulty in at least one of the following activities due to knee pain: lifting and carrying groceries, walking 400 meters, entering or exiting the chair or going up and down the stairs; or chronic knee pain with mechanical characteristics; or caused by degenerative cartilage Joint swelling, pain, stiffness, gait changes and history of exercise loss; 6) The patient has been given medication for the past three months. The drug includes anti-inflammatory drugs or analgesics; or the patient does not respond to the existing analgesic drugs and needs interventional therapy; 7) The patient is in good health except for knee symptoms; 8) The subject or his or her guardian is required to sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Study the history of joints or major trauma, fractures; 2) Study signs of inflammation at or around the joints, including: redness, fever, and a large amount of bulging fluid in the knee joint, accompanied by loss of normal contours of the joint; 3) Knee X-ray examination has other pathological damage; 4) Patients with severe incapacity or disability, ACR function rating is IV, or can not walk without auxiliary equipment; 5) Congenital or acquired malformation leads to severe knee deformity (inversion 30 (obesity class II); 8) The patient has coagulopathy, poorly controlled diabetes or other doctors believe it is a contraindication to interference with cartilage repair; 9) Patients have alcohol or drug abuse for nearly 6 months; 10) The patient has any potential or current medically-accepted mental illness (which may affect the assessment of the subject); 11) Uncontrolled bacterial, fungal or viral patients with severe systemic or local infection, including hepatitis A, hepatitis B, hepatitis C, HIV, syphilis positive patients; 12) Patients with severe cardiac dysfunction, such as left ventricular ejection rate < 50%; patients with right ventricular failure, arrhythmia and other dysfunction; 13) Uncontrolled high blood pressure or congestive heart failure, active angina requiring nitrate, myocardial infarction or arrhythmia or heart failure requiring active treatment in the past 6 months; 14) Patients with pulmonary hypertension; 15) Patients with diffuse alveolar hemorrhage and other progressive lung disease may need to maintain a blood oxygen level through a mask or other auxiliary machinery; hypoxemia, oxygen saturation < 90%; 16) Respiratory failure with restrictive or obstructive pulmonary disease or ventilator support; 17) In patients with severe liver dysfunction, alanine aminotransferase, total bilirubin is more than 3 times the normal maximum value; 18) Severe hepatic vein occlusive disease or sinus obstruction; 19) Severe renal insufficiency, creatinine is more than 2 times the normal maximum value; creatinine clearance is < 30 mL/min; 20) Pregnant women or patients planning to become pregnant, breast-feeding patients; 21) Patients who are participating in other clinical trials; 22) Severe allergies and patients known to be allergic to hyaluronic acid products; 23) The researchers believe that other reasons are not suitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Walking 20-meter pain visual analogue scale; | — |
Countries
China
Contacts
The First People's Hospital of Hefei